Cannabis Law Glossary
Cannabinoid FDA Regulation
Definition
The FDA has authority over CBD and other cannabinoids in food, dietary supplements, and drugs; it has determined that CBD in food and supplements is unlawful without explicit approval, creating regulatory uncertainty for the hemp-CBD industry.
FDA's Role in Cannabinoid Regulation
While the 2018 Farm Bill legalized hemp and hemp-derived cannabinoids, it explicitly preserved the FDA's authority under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act over cannabinoid-containing products. This has created significant regulatory uncertainty for the hemp-CBD industry.
The Drug Preclusion Problem
The FD&C Act prohibits selling a substance as a food or dietary supplement if that substance has been authorized for investigation as a new drug under an Investigational New Drug (IND) application — the "drug preclusion rule." Epidiolex, the FDA-approved CBD pharmaceutical for treatment-resistant epilepsy, means that CBD has been approved as a drug, which the FDA has argued precludes its addition to food or its sale as a dietary supplement under existing statutory authority.
FDA's Enforcement Posture
Rather than proactively rulemaking to create a legal pathway for CBD in food or supplements, the FDA has relied on enforcement discretion — generally declining to take action against low-potency CBD products while issuing warning letters to companies making disease claims or selling very high-potency products. In 2023, the FDA concluded that "a new regulatory pathway" is needed and called on Congress to act.
Congressional Response
Multiple bills have been introduced to create an explicit regulatory pathway for CBD in food and supplements. The most prominent proposals would establish a maximum serving size (typically 25mg), labeling requirements, and a notification process with the FDA.
Other Cannabinoids
FDA's position on cannabinoids beyond CBD — including CBG, CBN, and THC isomers derived from hemp — is less developed, though the agency has authority to evaluate them under the same framework.
THC and FDA
The FDA has approved two synthetic THC pharmaceuticals:
- Dronabinol (Marinol): Schedule III
- Nabilone (Cesamet): Schedule II
- Epidiolex: Schedule V (CBD-derived)
Related Terms
See also: [CBD Isolate](/glossary/cbd-isolate), [Full-Spectrum CBD](/glossary/full-spectrum-cbd), [2018 Farm Bill](/glossary/2018-farm-bill), [USDA Hemp Program](/glossary/usda-hemp-program)
Work With Hoban Law Group
CBD product regulatory strategy requires navigating both FDA and FTC requirements. [Schedule a consultation](/consultation?source=glossary&term=cannabinoid-fda-regulation).
Authoritative Sources
Work with Hoban Law Group
Schedule a consultation
Have questions about Cannabinoid FDA Regulation or how it applies to your business? Our team prepares a regulatory briefing before you speak. No cost. No commitment.
Engage Hoban Law Group